Collaboration on medical marijuana commences; $5M financing round for RNA therapeutics company;

> Isa Scientific signed an agreement focused on developing medical marijuana in collaboration with Yissum Research Development Company, the technology transfer company of the Hebrew University of Jerusalem, the technology transfer company of the Hadassah Medical Organization in Jerusalem, and the U.K.'s Kennedy Trust for Rheumatology Research. "It is important to recognize that very little CBD (cannabidiol) usually gets into the bloodstream when it is taken by mouth, and this inefficiency is a major obstacle to making oral CBD medicines with consistent dosing and reliable therapeutic outcomes. ISA Scientific has uniquely resolved this key problem with proprietary drug delivery technology now being integrated into our clinical trials. Besides maximizing the therapeutic utility of ISA Scientific's CBD formulations, this technology also helps reduce production costs and thus the price of medicine to patients," said Isa Scientific CEO Yaacov Michlin. More

> Germany's Rigontec GmbH announced it has raised €4.8 million ($5.27 million) to bring its series A round to €14.25 million ($15.64 million) in support of its RNA-based candidates to treat cancer and viral diseases. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.